FDA Brief

Warning letters Drugs

FDA warning letter to

Vegewax Candleworx Ltd.

High riskIssued Jun 14, 2024Posted Mar 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

What happened

FDA inspected the drug manufacturing facility in Concord, Ontario, from October 16 to 19, 2023. FDA found the company failed to test each component lot for identity and conformity with specifications, including its active pharmaceutical ingredient (API), and failed to adequately investigate out-of-specification potency and microbiological results. FDA called the company’s November 2, 2023 response inadequate.

What FDA found

  1. Failed to test each component lot for identity and conformity with all written specifications, including its API, and relied on supplier certificates of analysis without establishing their reliability.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Quality control released a batch that failed potency testing after adding more material and assigning a new batch number, without a thorough root-cause investigation or corrective and preventive actions.

    21 CFR 211.192
  3. Failed to adequately investigate multiple microbiological excursions in the water system and did not isolate and identify organisms or determine which batches could be contaminated.

    21 CFR 211.192
  4. Quality control failed to review and approve all production and control records before release or distribution.

    21 CFR 211.192

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days; the response should include a commitment to provide high-risk component test results no later than 30 calendar days from the letter. FDA also recommends a qualified CGMP consultant if the company intends to resume manufacturing drugs for the U.S. market.

Who should pay attention

  • U.S. drug manufacturers and contract manufacturers using high-risk components
  • brands and distributors selling OTC drug products made by this facility
  • suppliers and buyers relying on certificates of analysis for component identity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk